Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Leuk Lymphoma. 2020 Dec 28;62(5):1187–1194. doi: 10.1080/10428194.2020.1861270

Table 4.

Best response by diagnosis

Best response AML ALL MDS CML-BC Total

(number of patients)
Complete remission (CR) 1 0 0 0 1
Stable disease (SD) 12 1 4 1 18
Progressive disease (PD) 13 1 1 1 16
Not assessed / Not evaluable 2 0 1 0 3

Study participation discontinued prior to disease assessment timepoint (1 withdrew for personal reasons; 2 discontinued study treatment for unrelated adverse events)